Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Pembrolizumab & Colorectal cancer (CRC) (Mismatch Repair Deﬁciency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI))

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

In the context of Pembrolizumab & Colorectal cancer (CRC) (Mismatch Repair Deﬁciency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)), Pembrolizumab is approved by both FDA and EMA for Colorectal cancer (CRC) (Mismatch Repair Deﬁciency (MMR-d) / DNA Mismatch Repair / Microsatellite Instability (MSI)), with different lines of therapy specified.

FDA status

In May 2017, FDA granted a tissue‑agnostic approval of pembrolizumab for unresectable or metastatic MSI‑H/dMMR solid tumors, including colorectal cancer, that have progressed following prior treatment an…

References (Sources)

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Casak et al. 2021 Clin Cancer Res 27(17): 4680-4684
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies
Salama & Moschos 2017 Ann. Oncol. 28: 57–74
Review
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
André et al. 2020a NEJM 383: 2207-2218
Pembrolizumab in unresectable or metastatic MSI high colorectal cancer: safety and efficacy
Roth & Das 2021 Expert Review of Anticancer Therapy 21: 229-238
Review
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deﬁcient metastatic colorectal cancer (KEYNOTE-177): ﬁnal analysis of a randomised, open-label, phase 3 study
Diaz et al. 2022 The Lancet Oncology 23: 659-670
Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deﬁcient CRC
Jin et al. 2022a Future Oncology 18: 2155-2171
Meta-Analysis
Review
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
Trullas et al. 2021 ESMO Open 6(3): 100145

AI Chat

7/1/2026

Chat with our artificial intelligence: